Chronic Myeloid Leukemia (CML)NCT07740603
Study of CD38 and CD56 in Chronic Myeloid Leukemia
An observational study of Chronic Myeloid Leukemia (CML), run by Sohag University.
Trial summary
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow. The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia. Read more about this study
- Who is it for?
- Any ageHealthy volunteers can take part
- Conditions the study is for
- Chronic Myeloid Leukemia (CML)
- What is being tested?
- cd 38 and cd 56
- How many people
- 200 participants
- Where
- No sites listed yet
- Study dates
- 1 Sep 2026to 1 Jul 2027
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Study population: patients in sohag city
Who may be able to join
- patients with chronic myeloid leukemia
Who cannot join
- other hematological diseases
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Aberrant Expression of CD56 on CD38 Positive Neutrophils as a Novel Diagnostic Tool in Chronic Myeloid Leukemia
Chronic myeloid leukemia is a myelo-proliferative neoplasm characterized by abnormal proliferation of myeloid cells. There is an accumulation of mature granulocytes in the blood and bone marrow.
The aim of the study is to study expression of CD38 and CD56 in patients with Chronic myeloid leukemia.
- Conditions
- Chronic Myeloid Leukemia (CML)
- Being tested
- cd 38 and cd 56
- Medical subject headings
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
cd 38 and cd 56Diagnostic test
prescence of high percentage of cd38 and cd 56
| Study group | Role | What they receive |
|---|---|---|
| chronic myeloid leukemia group | Not described Receives: Diagnostic Test: cd 38 and cd 56 | |
| healthy group | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
an increased change in cd 38 and cd 56 in chronic leukemic patients
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Jul 2026
- Study start1 Sep 2026 (estimated)
- Primary completion1 Jun 2027 (estimated)
- Study completion1 Jul 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Chronic Myeloid Leukemia (CML)Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Prospective
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mennatallah Mostafa Zaki, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07740603
- Sponsor's protocol ID
- Soh-Med-26-6-9MS
- Status last verified
- Aug 2026
- First submitted
- 25 Jul 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Individual data sharing
- Undecided